People: Invion Ltd (IVX.AX)
20 Nov 2019
Dr. Gregory R. Collier, Ph.D. is re-designated as Non-Executive Director of the Company, effective 31 October 2019. He is no longer Chief Executive Officer, Managing Director, Executive Director of the Company, effective 31 October 2019. He has more than 20 years experience spanning operational, clinical and scientific aspects of pharmaceutical research, development and commercialization. He has led the planning and execution of multiple commercial transactions including in and out licensing deals and M&A activities, and he has taken a drug from discovery through to regulatory approval. Prior to his commercial pharmaceutical career, Dr. Collier had an academic career resulting in over 150 peer reviewed publications, and senior authorship on 33 patents. Dr Collier was the inaugural Alfred Deakin Professor at Deakin University, and also held positions at Melbourne University, Monash University and the University of Toronto. In 2010, Dr. Collier was awarded the Roche Award of Excellence for his contribution to the biotechnology industry.
|Total Annual Compensation, AUD||46,739|
|Restricted Stock Award, AUD||--|
|Long-Term Incentive Plans, AUD||--|
|All Other, AUD||4,207|
|Fiscal Year Total, AUD||50,946|